Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

NCT05717166 is registered in ClinicalTrials.gov with David Palma as lead sponsor.

NCT NCT05717166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05717166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
Lead sponsor
David Palma
Phase
Phase 3
Overall status
Recruiting
Start date
October 6, 2023
Completion date
April 30, 2029
Enrollment
180 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic tumor